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DeliveryNanoscale celluloses have recently gained an increasing interest in modern medicine. In this study, we
investigated the properties of plant derived nanoﬁbrillar cellulose (NFC) as an injectable drug releasing
hydrogel in vivo. We demonstrated a reliable and efﬁcient method of technetium-99m-NFC labeling,
which enables us to trace the in vivo localization of the hydrogel. The release and distribution of study
compounds from the NFC hydrogel after subcutaneous injection in the pelvic region of BALB/c mice were
examined with a multimodality imaging device SPECT/CT. The drug release proﬁles were simulated by
1-compartmental models of PhoenixWinNonlin. The NFC hydrogel remained intact at the injection site
during the study. The study compounds are more concentrated at the injection site when administered
with the NFC hydrogel compared with saline solutions. In addition, the NFC hydrogel reduced the
elimination rate of a large compound, technetium-99m-labeled human serum albumin by 2 folds, but
did not alter the release rate of a small compound 123I-b-CIT (a cocaine analogue). In conclusion, the
NFC hydrogels is easily prepared and readily injected, and it has potential use as a matrix for controlled
release or local delivery of large compounds. The interactions between NFC and speciﬁc therapeutic
compounds are possible and should be investigated further.
 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The use of hydrogels as nanostructured scaffolds and particles
in tissue engineering and delivery of therapeutic agents is an
emerging ﬁeld in biomedicine (Geckil et al., 2010; Lu et al.,
2013), as many hydrogels have innate structural similarities with
physiological matrices (Slaughter et al., 2009). However, there is
an ongoing research to improve the properties and quality of these
applications, such as structural integrity, biocompatibility, and bio-
degradability. Recently, cellulose and cellulose-based materials
have gained an increasing interest in modern medicine, mostly
due to their versatility and inherent properties (Charreau et al.,
2013).
Cellulose is the most abundant naturally occurring biopolymer
on earth. The discovered structural features and properties have
enabled the creation of novel cellulose-based materials and appli-
cations, particularly the emerging investigation of nanoscale cellu-
loses (Charreau et al., 2013). The cellulose nanomaterials, mostly
ﬁlms and hydrogels, have already shown importance in industrial,
pharmaceutical, and biomedical research (Klemm et al., 2011). Inthe biomedical ﬁeld, injectable hydrogels have shown some poten-
tial (Jain et al., 2013); especially considering the challenges of non-
invasive delivery of peptide and protein therapeutics, such as
monoclonal antibodies and recombinant human proteins (Jain
et al., 2013; Kumar et al., 2006; Muller and Keck, 2004).
Modern medicine involving drug delivery and therapy with
implants and hydrogels, the applications must be non-toxic and
biocompatible, while still providing the desired properties and
functions for successful treatment. Currently, the modern medicine
related research on nanostructural cellulose hydrogels has mostly
focused on the use of bacterial celluloses (Innala et al., 2013;
Muller et al., 2013; Pretzel et al., 2013). However, plant-derived
nanoﬁbrillar cellulose (NFC) prepared from wood pulp is also one
of the emerging nanomaterials with properties for potential bio-
medical applications (Bhattacharya et al., 2012). High water con-
tent of NFC, like with many hydrogels, provides soft tissue like
mechanical behavior and similarity, which inherently improves
biocompatibility (Jain et al., 2013). Furthermore the viscoelastic
properties of NFC resemble the physiological properties of extra-
cellular matrices (Bhattacharya et al., 2012; Miron-Mendoza
et al., 2010). The NFC aqueous suspensions behave as 1-compart-
mental hydrogels with pseudoplastic and thixotropic properties
(Pääkkö et al., 2007). Pseudoplasticity induces a shear thinning
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thinning therefore enables NFC hydrogels to be easily injected
(Bhattacharya et al., 2012) as the extruding force of the syringe is
enough to change NFC ﬂow properties to lower the viscosity. While
in static conditions, NFC retains higher viscosity due to the rear-
rangement of the ﬁbers, which reverts the shear thinning effect.
As an injectable hydrogel, NFC is able to deliver cells or therapeutic
agents (e.g. proteins or peptides) into easily accessible target sites,
such as under the skin. Additionally NFC hydrogels are biocompat-
ible, non-toxic, and structurally durable (Märtson et al., 1999;
Vartiainen et al., 2011). As a plant derived material, the NFC hydro-
gels are obtained from a non-animal and non-human source, being
thus xeno-free. Additionally, cellulose based materials offer a
broad modiﬁcation capacity (Klemm et al., 2011), which is advan-
tageous when designing new biomaterials.
Currently, in biomedical and -pharmaceutical research, the
hydrogels under investigation for the potential use of controlled
release matrices can prove to be problematic in terms of gel activa-
tion properties (Hennink and van Nostrum, 2002), especially with
injectable hydrogels. The need for an external source of activation
presents additional complications and toxicity as crosslinking
agents often used are potentially toxic compounds (Van Tomme
et al., 2008), that need to be extracted from the gels before usage.
This could prove to be difﬁcult in the case of parenteral delivery,
such as subcutaneous injections. Furthermore, the crosslinkers
may react with the imbedded drug compounds within the hydro-
gel, which may result to unwanted consequences or ineffective
treatment. NFC overcomes this obstacle, as there is no need for
activation methods such as the use of UV irradiation or chemical
crosslinking due to the pseudoplasticity of the material. After
administration (e.g. subcutaneous injection), NFC ‘‘gels’’ spontane-
ously, as the ﬁbers rearrange to form a viscous gel; therefore avoid-
ing all the complications with removing the crosslinking agents,
potential toxicity or interactions between the crosslinking agents
and the drug compounds in use.
The aim of this study was to investigate the properties of plant-
derived NFC hydrogel as an injectable platform or ‘‘implant’’ for
drug release, in addition to examine the utility of SPECT/CT imag-
ing to illustrate the behavior of hydrogels in vivo. We investigated
the use of NFC hydrogel as a potential device for local delivery and/
or sustained drug release in an in vivo study with the use of BALB/c
inbred mice. Furthermore the use of radiolabeled wood pulp NFC
hydrogel as a potential biomedical device amongst other biomed-
ical applications has not been demonstrated before. However, the
biocompatibility and toxicity of bacterial and plant-derived cellu-
lose materials have been documented both in vitro and in vivo
use with of small animals (Märtson et al., 1999; Vartiainen et al.,
2011; Alexandrescu et al., 2013; Roman et al., 2010; Kovacs
et al., 2010; Pértile et al., 2011; Helenius et al., 2006; Moreira
et al., 2009). In addition, we demonstrate a reliable and efﬁcient
method for NFC radiolabeling for the purpose of molecular imaging
with a small animal SPECT/CT.
2. Materials and methods
2.1. 99mTc-NFC labeling
To image NFC in animals by SPECT/CT, NFC was labeled with
99mTc-NFC according to a previously described procedure for
99mTc-labeled carboxymethyl-cellulose (Schade et al., 1991) with
slight modiﬁcations. 1.6% NFC stock hydrogel (GrowDex, UPM-
Kymmene Corporation, Finland) was used to prepare 1% NFC
hydrogel with added stannous chloride stock (17.5 lg/ml in saline
solution) and 99mTc-pertechnetate (99mTcO4) stock (80 MBq/ml
in saline solution) to a ﬁnal volume of 1 ml. Brieﬂy, 590 ll of the
stock NFC was added to 285 ll of stannous chloride dehydratesolution (Angiocis, IBA Molecular, Belgium) followed with
10 min incubation and mixing. Subsequently, 125 ll of 99mTcO4
was added to the reaction mixture to reach the NFC concentration
of 1% and incubated while mixing for 30 min.
To optimize the method for 99mTc-NFC labeling, various condi-
tions were tested during the labeling procedure, such as buffer
pH ranging from 4.74 to 8.05, different incubation times for
99mTcO4/NFC reaction mixture (5, 10, 15, 20, 25 and 30 min) and
stannous chloride concentrations ranging from 50 to 0.05 lg/ml.
The stability of the radiolabel was investigated in neutral iso-
tonic pH by incubating the 1% 99mTc-NFC samples for 24 h. Samples
were prepared in stock solutions as described above in saline or in
fetal bovine serum (FBS) (Sigma–Aldrich, Finland). Radiochemical
purity and efﬁciency was tested at every time point (0, 15, 60,
120, 240 min and 24 h).
TLC determined labeling efﬁciency and radiochemical purity of
99mTc-NFC with ITLC-SG chromatography plates (Agilent Technolo-
gies, Santa Clara, CA, USA) in methylethylketone (MEK) solvent sys-
tem. Plates were cut in smaller equally sized pieces and placed in
standard RIA tubes for radioactive measurement with a gamma
counter (RiaCalc. WIZ, Wallac 1480 WIZARD 300, Finland).
2.2. In vivo imaging, drug release and kinetics
Animal studies were approved by the Finnish National Animal
Experiment Board and performed in accordance with the Animal
Welfare Act (247/1996) and Good Laboratory Practices for
Animal Research. The release properties of plant-derived NFC
implants were investigated with the use of radiolabeled small
compounds. The use of 99mTc-NFC allows localization of the NFC
in animals. Hydrogel implants were injected subcutaneously in
the pelvic region, and the mice were observed non-invasively over
a 24 h period with the use of a SPECT/CT system. After the 24 h
period, the mice were sacriﬁced by cervical dislocation.
A total of 20 female BALB/c inbred mice were obtained from a
professional stockbreeder (Harlan Laboratories, Netherlands) and
quarantined for two weeks prior to the start of the experiment.
The mice were divided into 7 groups, A, B, C, D, E, F (n = 3) and G
(n = 2). The mice in groups A and C were injected with a mixture
of saline solution and Iodine-123-Sodium Iodine (123I-NaI) or with
a cocaine analogue Iodine-123-(2-beta-carbomethoxy-3-beta-(4-
iodophenyl)-tropane) (123I-b-CIT) (MAP Medical Technologies Oy,
Finland), respectively. The mice in groups B and D were injected
with a 5:1 mixture of 1% NFC and 123I-NaI or 123I-b-CIT, respec-
tively (ﬁnal mixture of 0.83% NFC hydrogel with added study
compound). Group E was injected with a mixture of 123I-NaI and
99mTc-NFC for dual-radionuclide SPECT/CT. Groups F and G were
injected similarly with 5:1 mixture of 1% NFC and 99mTc-labeled
human serum albumin (HSA) (Sigma–Aldrich, Finland) or
99mTc-labeled HSA in a saline solution, respectively (ﬁnal mixture
of 0.83% NFC hydrogel with added study compound). All mice
received 50–60 MBq/200 ll injections.
99mTc-HSA was prepared, and radiochemical purity was tested
according to the manufacturer’s instructions (Vasculocis, CIS bio
international, France). Radiochemical impurities were found below
the allowed 5% of the total activity.
SPECT/CT imaging was performed with a four-headed small ani-
mal scanner (NanoSPECT/CT, Bioscan, USA), outﬁtted with
1.0 mm multipinhole apertures. All mice were sedated with isoﬂu-
rane, and SPECT images were acquired 0 h (with 5 or 6 acquisitions
at 15 min intervals), 5 h and 24 h post-injection in 16 projections
using time per projection of 45, 90 and 180 s, respectively. CT
imaging was accomplished with 45 kVp tube voltage in 180 projec-
tions. For 3D co-registration and analysis, the SPECT images were
reconstructed with HiSPECT NG software (Scivis GmbH, Germany)
and fused with CT datasets by using the molecular imaging suite
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ests (VOI’s) were drawn at the injection site (whole NFC implant),
thyroid glands, stomach, left kidney, heart, and around the stria-
tum depending on the study compound, respectively. Counts
within each VOI were recorded, corrected for radioactive decay,
and normalized to the activity at the time of injection.
99mTc-HSA release kinetics was described using the built-in 1-
compartmental models of Phoenix WinNonlin (Pharsight,
Mountain View, USA). The saline preparations were assumed to
be 100% available for absorption immediately after injection. The
pharmacokinetic (PK) data obtained from the saline injections
were observed against the data obtained from the hydrogels.
Deconvolution and Loo–Riegelman models were selected to dem-
onstrate 99mTc-HSA release, or the amount ready to be absorbed,
from the injected hydrogel.3. Results
3.1. 99mTc-NFC labeling
99mTc was chosen to label NFC based on the previous ﬁnding
showing the binding of 99mTc to carboxymethyl-cellulose (Schade
et al., 1991). To optimize the labeling condition, we investigated
the following parameters: the concentration of stannous chloride
solution required for the reduction of 99mTc (Fig. 1a), the pH of
the labeling solution (Fig. 1b), and the time required for the label-
ing reaction to occur efﬁciently (data not shown). Stannous chlo-
ride at 5 lg/ml is shown to be the most optimal; however, the
labeling procedure was fairly insensitive towards the concentra-
tion changes, and no major effect on labeling efﬁciency was found
between the concentrations of 50 and 0.5 lg/ml (Fig. 1a). For fur-
ther studies, the optimal 5 lg/ml stannous chloride concentration0
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Fig. 1. The effect of the amount of stannous chloride and pH in 99mTc-NFC
radiolabel preparation. (A) No major differences were found between the concen-
tration levels of 50–0.5 lg/ml of stannous chloride. Optimal concentration was
found at 5 lg/ml and used in the later phases of this study. (B) The labeling solution
pH levels between 4.74 and 8.05 did not show any clear effects in the ﬁnal
radiolabeling efﬁciency. The labeling solution pH of 7.2 was used in the animal
studies.was selected. In addition, the changes of pH in the labeling solu-
tions were investigated during the radiolabel preparation. It was
observed that the tested pH levels did not have any noticeable
effect on the labeling efﬁciency (Fig. 1b). Throughout the pH range
of 4.74–8.05, the labeling efﬁciency was found well over 95%. The
saline solution (pH of 7.2) was selected for animal studies. Further-
more the incubation times before the TLC radiolabel purity conﬁr-
mation were examined. It was shown that the incubation times
less than 30 min were suboptimal (data not shown). Therefore
30 min incubation time was selected for further studies.
The described 99mTc-NFC labeling method for the aforemen-
tioned parameters was found highly efﬁcient; typically resulting
in over 95% binding rate, while less than 5% of the technetium
remained unbound (Fig. 2). Reference samples without stannous
chloride showed little binding efﬁciency. In addition NFC did not
show any inherent binding afﬁnity towards 99mTc.
In preparation for the in vivo animal experiment, the radiolabel
stability was studied for a period of 24 h in both saline and fetal
bovine serum (FBS) samples (Fig. 3). 99mTc-NFC was shown to be
stable in FBS during the 24 h period. In contrast, the radioactivity
of the labeled NFC in saline at the 24 h time point was reduced
to 40.5%. During the ﬁrst 4 h, the overall radioactivity of 99mTc-
NFC remained at 81.7% and 87.2% for saline and FBS samples,
respectively. Therefore it can be expected that the radiolabel will
remain stable during the ﬁrst stages of the SPECT/CT imaging;
however some consideration has to be taken into account while
examining the 24 h data.3.2. In vivo imaging, drug release and kinetics models
The location of the NFC hydrogel after injection was investi-
gated with a dual-trace SPECT/CT imaging of 123I-NaI and 99mTc-
NFC. Images conﬁrm the hydrogel position at the injection site in
the pelvic region (Fig. 4). In addition, the NFC hydrogel remained
intact during the image acquisition. In between the ﬁrst set of
images and the 5 h images, the mice were awake andmoving freelyFig. 2. The labeling efﬁciency of NFC with 99mTc-pertechnetate. Typically over 95%
binding was observed. Samples that were not treated with stannous chloride
showed poor labeling efﬁciency (Ref.), suggesting that NFC does not have an
inherent binding afﬁnity towards the radiolabel in its unoxidized state. With the
absence of NFC the free 99mTcO4 does not remain at the point of application (shown
on the SPECT/CT image taken from a TLC sheet). When NFC is introduced with
99mTcO4, only a small portion of the radiolabel is shown unbound.
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Fig. 3. The stability of the 99mTc-NFC radiolabel during a 24 h period. (A) The
sample prepared in FBS remained relatively stable during the whole experiment;
however the sample prepared in saline showed a major decrease of labeling
efﬁciency at the end point of the study. (B) The overall labeling efﬁciencies suggest
that both samples are stable during the ﬁrst 4 h after sample preparation.
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nor disintegrate. Furthermore, the radiolabel showed stability as
predicted from the previous radiolabel stability experiment
(Fig. 3), and the pertechnetate remained at the injection site bound
to the NFC hydrogel. 123I-NaI was mostly distributed into the thy-
roid glands and stomach, in addition to being excreted to urine. 5 h
post injection, no trace of 123I-NaI was found at the injection site.
To explore the use of the NFC hydrogel as a drug release matrix,
we selected a small drug (123I-b-CIT) and a large protein drug
(99mTc-HSA) to evaluate the effect of molecule size on the rate of
release from the NFC hydrogel. The in vivo release and distribution
of 123I-b-CIT and 99mTc-HSA were investigated after injecting the
NFC hydrogels imbedded with the study compounds. The study
compound and saline solution mixtures were used as controls
(injections without the NFC hydrogel).
The differences between the HSA–NFC hydrogel ‘‘implants’’ and
saline injections were observed as 99mTc-HSA expressed a delayed
release from the NFC hydrogel and 41% of the injected dose
remained within the hydrogel 5 h post injection (Fig. 5a). Linear
release was observed in the beginning of the study, and release
rates calculated from the early time points (from ﬁrst to 5 h)
resulted in 0.0233 lg/h and 0.0139 lg/h for saline solution
and hydrogel injections, respectively. Release of 99mTc-HSA was
steady during the whole study. In addition, a large distribution of
99mTc-HSA was shown in the subcutaneous tissue surrounding
the injection site indicating a very poor absorption of 99mTc-HSA
into the circulatory system (Fig. 5b). Slight activity was detected
within the bloodstream, as indicated by the radioactivity in heart
and left kidney (Fig. 6). However, the distinctions between the
compound itself and its metabolites cannot be made, as it is well
known that 99mTc-HSA does not pass the glomerular ﬁltration
under normal renal activity. Slow absorption is probably due tothe large protein size and low enzymatic activity within the subcu-
taneous tissue. It was shown that injections given with NFC hydro-
gel retained 99mTc-HSA in a smaller area within or around the
hydrogel than saline solution injections (Fig. 5b), therefore 99mTc-
HSA did not freely distribute into the subcutaneous tissue. This
might indicate that rate of release from the hydrogel is limiting
99mTc-HSA absorption.
Heart and the left kidney were selected to estimate the
99mTc-HSA absorption into the cardiovascular system. No apparent
accumulation of 99mTc-HSA to any other organ was detected. No
differences between the saline and hydrogel injections were
observed in blood pool activity, i.e. heart (Fig. 6a). However, slight
differences were detected in the left kidney of the study animals
(Fig. 6b). The amount accumulated in the left kidney during the
study period was low in addition to some of the activity might
be due to metabolized 99mTc-HSA. However the differences
indicate a slower absorption from the NFC hydrogel injections.
Therefore the limited distribution (smaller surface area) might
explain the lower absorption rate from the 99mTc-HSA/NFC.
To better understand the release proﬁle of 99mTc-HSA from the
NFC hydrogel, we performed pharmacokinetic simulation by using
the built-in 1-compartmental models of PhoenixWinNonlin. We
used both deconvolution and Loo–Riegelman models to depict the
fraction that is ready to be absorbed from the initial injection site,
i.e. the hydrogel. Both models show similar proﬁles, in addition to
most of the dose being ready for absorption at the 24 h time point.
Both pharmacokinetic models built for 99mTc-HSA showed an
absorbed fraction of 0.43 over 15 min post-injection (Fig. 7).
The release was shown as 1st order kinetics. The computational
elimination rate constants were 0.108 h1 and 0.209 h1 from the
hydrogel and saline solutions, respectively (Supplementary
Table 1); therefore showing a 2-fold slower rate of elimination of
99mTc-HSA from the injection site when given with the hydrogel.
It should be noted that the absorbed fraction depicted in the phar-
macokinetic models does not describe the absorption that was
seen in the SPECT/CT images, but rather the distribution within
the subcutaneous tissue. The SPECT/CT images show a clear signal
for 99mTc-HSA at 24 h post-injection.
In contrast to a larger compound, 99mTc-HSA that showed a
slow release from both NFC hydrogel and saline mixture (Fig. 5),
the small compound 123I-b-CIT was released rapidly from the
NFC injections (Fig. 8). 5 h post-injection 123I-b-CIT had been com-
pletely released from the NFC matrix. Slightly slower release was
observed with 123I-b-CIT/NFC hydrogels compared to the 123I-b-
CIT/saline injections; however the differences were not apparent.
A similar effect was observed with 123I-b-CIT than with 99mTc-
HSA, as the NFC hydrogel retains the study compound within itself
and a smaller area than with the saline injections. Therefore a bet-
ter indication for smaller compounds with the use of NFC hydro-
gels might be local delivery rather than delayed delivery which
was observed with the larger compound 99mTc-HSA.
In summary, the release rate and distribution of 99mTc-HSA
indicated a clear difference between the NFC hydrogels and saline
solutions. The NFC hydrogel caused a 2-fold slower rate of elimina-
tion of 99mTc-HSA from the injection site. The release was shown to
be steady during the 24 h study period. Poor absorption was
observed, as 99mTc-HSA distributed mostly in the subcutaneous tis-
sue surrounding the injection site if given with saline solution. The
SPECT/CT images show that both study compounds 123I-b-CIT and
99mTc-HSA are more concentrated at the injection site when
administered with the NFC hydrogel compared with saline solu-
tions. 24 h post-injection small amounts of 123I-NaI dose were
found in the thyroid glands for both saline and NFC hydrogel injec-
tions. 123I-b-CIT was mostly distributed into the striatum. Other
distribution into speciﬁc organs in the periphery was unclear,
and no other organs were selected to investigate within this study.
Fig. 4. The release of 123I-NaI from 99mTc-NFC injections. Above: dual tracing images showing implant (red) placement and test compound release. Below: 30 min image split
to visualize both radiotracers separately and the 5 h dual tracing image. 99mTc-NFC does not seem to disintegrate, migrate or absorb into the bloodstream, although the study
animals have been moving freely before the 5 h images. The NFC injections are functioning like drug releasing ‘‘implants’’.
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In this study, the drug release properties of a plant-derived NFC
hydrogel, GrowDex, as an injectable biomaterial were evaluated.
NFC samples were imbedded with the labeled study compound
for SPECT/CT small-animal imaging, in addition to dual-radionu-
clide tracing to conﬁrm the in vivo localization of the hydrogel.
Subcutaneous administration in the pelvic region was selected as
the most appropriate and convenient for hydrogel implantation.
Injections under the skin can overcome some of the delivery prob-
lems related to new biopharmaceutical drugs, such as recombinant
human proteins or monoclonal antibodies (Kumar et al., 2006;
Muller and Keck, 2004). Additionally, the study compound 99mTc-
HSA would be exposed to the high proteolytic activity in the gut
through oral administration. Furthermore, as the native NFC is
not naturally degraded in mammals, the subcutaneous site was
selected to enable easier later removal of hydrogel implants.
First, we investigated the labeling efﬁciency of NFC with 99mTc.
The results indicate that after optimization the labeling method
showed a high binding rate with less than 5% remaining unbound;
therefore achieving a very high binding efﬁciency. It is possible
that the unbound pertechnetate accumulates in the thyroid glands;
however the amount (and therefore the signal) remained negligi-
ble when compared to 123I-NaI, which is generally known toaccumulate heavily into the thyroid. Additionally, 99mTc was not
detected in the thyroid glands in its respective channel in the split
images (30 min image in Fig. 4). It is not fully known what the ﬁnal
complex is between cellulose and technetium; however we pro-
pose the formation of a chelate complex between NFC and the
transition metal technetium that is reduced by stannous chloride,
which is a generally used radioactive labeling method (the techne-
tium reduction method). The reduced form Tc4+ will form chelate
complexes with NFC in the presence of O atoms in the OH groups
as it is known that the native NFC is slightly anionic (Kolakovic
et al., 2012; Wang et al., 2011). Furthermore it has been shown that
cellulose is capable of forming chelates with other transition met-
als (Kennedy et al., 1974). We propose that the Tc4+ aligns itself
between the cellulose molecule chains where the natural inter-
chain bonds take place.
The dual-radionuclide tracing SPECT/CT images showed that the
NFC implants had remained in their site of implantation during the
whole study. The mice have been awake and moving in between
acquisitions, which indicate that the NFC hydrogel implants were
resisting movement without deforming and did not migrate within
the subcutaneous tissue. This suggests that the 0.83% NFC hydrogel
is enough to enable ﬁber rearrangement to revert the shear thin-
ning effect of the extruding force in the needle after administra-
tion, which additionally reduces migration of the material within
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Fig. 5. The release rate of 99mTc-HSA from saline and NFC injections (% of dose). (A) 99mTc-HSA showed a slower release proﬁle than the smaller study compounds. In addition,
a slower release from the NFC hydrogels in comparison to the saline mixtures was observed. The release proﬁles for both saline and implant injections were steady. (B) SPECT/
CT images of 99mTc-HSA release from saline (above) and NFC injections (below). NFC hinders the distribution of 99mTc-HSA within the subcutaneous tissue. In addition
absorption is slow from both injections, probably due to the large size of the protein, and low enzymatic activity within the subcutaneous tissue. (C) In the 5 and 24 h SPECT/
CT images of 99mTc-HSA saline (left) and NFC injections (right) 99mTc-HSA is localized in the NFC implants, and its distribution in the subcutaneous tissue is much lower than
in the saline injections. In addition, it was shown that larger amount of 99mTc-HSA was still present within the hydrogel at 24 h, which indicates a slower rate of release from
the NFC hydrogels than from the saline injections.
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Fig. 6. The blood pool imaging of 99mTc-HSA. (A) Low activity in the heart suggested
poor 99mTc-HSA absorption from the injection site. No differences between the
saline and NFC hydrogel injections were observed. (B) The accumulation of 99mTc-
HSA in the left kidney was low for both saline and NFC hydrogel injections. The
activity in the left kidney might be due to metabolized 99mTc-HSA. However, it also
indicates a slower absorption of 99mTc-HSA from the NFC hydrogels, which
according to the SPECT/CT images, is due to NFC hindering the subcutaneous
distribution of 99mTc-HSA.
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Fig. 7. Pharmacokinetic models showing the estimated fraction ready to be
absorbed during the time scale of the study. Deconvolution and Loo–Riegelman
models help in estimating the rate of release of 99mTc-HSA from the hydrogel. Initial
release is rapid until the immediate area surrounding the hydrogel is reached, from
which after new drug molecules are introduced at a considerably slower rate to the
surrounding tissue.
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indicated that the NFC hydrogels did not degrade or deform as
no pertechnetate was observed outside the site of injection, which
is supported by the previous studies on cellulose biodurability
(Märtson et al., 1999), ﬂexibility, and structural integrity (Pääkkö
et al., 2008). As a non-biodegradable material in the mammalian
body, NFC could ﬁnd potential use as a surgical tissue adhesive,
space-ﬁlling injectable biomaterial for tissue repair, long-term orsingle-dose local drug delivery, and tissue engineering. However,
non-biodegradability is generally not desired. The removal of
NFC from easily accessible sites (such as from subcutaneous tissue)
through surgical means is fairly simple. In addition, the area could
be locally treated with cellulose degrading enzymes to disintegrate
the NFC hydrogels yielding mostly glucose as the metabolized
product. It has been shown that enzymatic degradation of NFC
with cellulase is possible without increasing in vitro cytotoxicity
(Lou et al., 2014). However, patient acceptance towards injections
is generally poor. Therefore NFC hydrogels have potential as long-
term or single-dose local delivery systems, especially with com-
pounds of poor bioavailability or where non-invasive routes
remain a challenge.
The release and distribution of 123I-b-CIT (a cocaine analogue)
from NFC hydrogel implants were evaluated. 123I-b-CIT showed
rapid release from the hydrogels, mostly distributing into the stri-
atum and slightly around the hydrogel at the injection site. 123I-b-
CIT showed a slightly slower rate of release when imbedded with
the hydrogel as opposed to the injections of saline and drug com-
pound solutions. However, due to the rapid release, we determined
that 123I-b-CIT does not show an apparent binding afﬁnity to nano-
ﬁbrillar cellulose itself. In addition, no major differences were
found in the distribution of 123I-b-CIT between the NFC/study com-
pound injections and the saline/study compound injections. There-
fore it is possible that the release of similar small compounds
might not be altered by the NFC matrix. However it seems that
the NFC hydrogel retains most of the 123I-b-CIT around itself and
does not distribute as easily into the surrounding subcutaneous
tissue than with the saline injections. We found it interesting that
without affecting much of the release rate of the study compound,
123I-b-CIT is still more localized when administered with NFC.
The release rate of the 99mTc-HSA was shown much slower than
the release rate of the smaller study compound 123I-b-CIT. In addi-
tion, a very poor absorption from the injection site into the circu-
lation was observed; furthermore, 99mTc-HSA distributed heavily
into the surrounding subcutaneous tissue. The release rate of
99mTc-HSA was steady during the whole study period; however,
slower release was observed with the NFC hydrogel injections than
with the saline injections. This suggests that NFC as an injectable
drug releasing biomaterial is indeed more suitable for larger com-
pounds, such as macromolecular protein and peptide drugs. Addi-
tionally, protein drugs suffer from delivery problems, which need
to be overcome for effective treatment (Jain et al., 2013). As an
injectable hydrogel, NFC could solve some of the challenges related
to the delivery of biopharmaceuticals.
The pharmacokinetic models that we constructed could be used
to further evaluate the release properties of NFC or other biomate-
rials in conjunction with SPECT/CT imaging. In our study the
deconvolution and Loo–Riegelman models described the amount
ready to be absorbed, which relates to the release rate of the com-
pound. This could be useful in further analyzing poorly absorbing
compounds (such as the HSA in our case), and can be used to com-
plement drug-biomaterial studies when small-animal imaging is in
use. This is especially true in situations where poor absorption is
the reason for an apparent slow rate of release, which might be
an erroneous indication by the SPECT/CT. Therefore, the detected
activity at the injection site might not be because of slow rate of
release from the biomaterial, but actually due to very poor
absorption.
As we proposed earlier, the high biodurability of NFC suggests
that as for a non-biodegrading material, it could have a potential
use as a long-term drug releasing biomaterial; ideal as an extended
release product for chronic diseases. In addition, NFC hydrogels
imbedded with therapeutic compounds could ﬁnd a potential
application as a local delivery biomedical device. Topical and sub-
cutaneous conditions could be treated with easily injectable NFC
Fig. 8. 123I-b-CIT was shown to be more concentrated at the injection site with NFC injections. Saline injections distributed to a wider area inside the subcutaneous tissue.
NFC retains both of the study compounds (99mTc-HSA and 123I-b-CIT) to a smaller area; however the differences in rate of release/absorption for 123I-b-CIT were small between
the injections. This suggests a possible application for local delivery rather than delayed release for smaller compounds used with NFC hydrogels.
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continuous release of drug from the hydrogels could be further
improved through formulation processes, in addition, nanoﬁbrillar
cellulose has not shown cytotoxic properties in previous studies
(Vartiainen et al., 2011; Alexandrescu et al., 2013; Pitkänen et al.,
2010), which supports the idea of NFC as a potential biomaterial.
However, it should be noted that studies considering the safety
of plant-derived NFC in humans have not been done and especially
with possible long-term exposure, this should be investigated
thoroughly.
The possible chemical interactions between proteins and NFC
should be investigated individually. NFC contains many hydroxyl
groups as well as some carboxyl groups which might interact with
the drug compounds imbedded within the matrix; therefore mak-
ing the predictions of release proﬁles difﬁcult for different com-
pounds. However, considering the current increase of interest in
pharmaceutical research towards the possibilities of macromolec-
ular protein and peptide drugs, NFC might offer an additional
method for parenteral delivery, as the effective delivery of protein
drugs has been one of the main challenges in pharmaceutical sci-
ences (Kumar et al., 2006). It is likely that the native NFC requires
modiﬁcation to perform more effectively in protein delivery. How-
ever cellulose based materials are highly modiﬁable (Klemm et al.,
2011), with which it is possible to improve the properties of NFC in
drug release and retaining.Furthermore, this study did not focus on physical nor chemical
properties of the molecules; however the native NFC is known to
have a slight negative surface charge (Kolakovic et al., 2012;
Wang et al., 2011), thus it can be expected to have some repelling
forces between the negatively charged 123I-NaI and 99mTc-HSA.
Indeed, the results indicated that in the dual-radionuclide imaging
study, the release of 123I-NaI was more rapid from the hydrogels
than from the control saline injections. The chemical properties
are more important in smaller scale, thus the repulsion forces by
the negative charges are greater than the hindrance of the nanoﬁ-
brous matrix of the hydrogel itself, which relates to molecular size,
a physical factor. 99mTc-HSA also has a negative charge; however
the size of the molecule is considerably larger than 123I-NaI, there-
fore the physical effect of the NFC matrix in the controlled release
is more dominant. Positively charged molecules were not investi-
gated in this study, however considering the effects of the nega-
tively charged molecules (123I-NaI and 99mTc-HSA); it is likely
that a more noticeable sustained release effect would be observed
with positively charged molecules.
In addition, during the study on 99mTc-HSA and hydrogel prep-
arations, it is unlikely but possible that a small amount of the free/
unbound pertechnetate from the HSA radiotracer would label the
NFC matrix while mixing the 99mTc-HSA solutions with the bioma-
terial prior to injection. The labeling for both 99mTc-HSA and 99mTc-
NFC utilized spontaneous stannous chloride reduction methods;
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In the case of erroneous biomaterial labeling during the study,
results would show as a false positive data of slower 99mTc-HSA
release from the biomaterial, as some of the NFC would be labeled
to 99mTc-NFC instead of the 99mTc-HSA. However, during the radio-
chemical purity test of the 99mTc-HSA, the amount of free pertech-
netate was observed very low (impurities were found below the
allowed 5% indicated by the manufacturer). Therefore, only the free
portion of the radiolabel amongst the impurities of the total activ-
ity is theoretically able to form bonds with the NFC biomaterial,
which would still amount to much less than 5% of the whole activ-
ity. This suggests that the 99mTc-HSA related data obtained in this
study is still reliable, as the amount of possible erroneous activity
detected from the biomaterial during the image acquisition is con-
siderably lower.
Most injectable biomaterials are prepared in solution, while the
gelation is triggered by an external signal, for example phototrig-
gering (Zhang et al., 2002) or salt- and pH-sensitive self-assembly
(Collier and Messersmith, 2004). In addition many crosslinking
agents are known to be toxic (Speer et al., 1980). Therefore the
removal of the potentially toxic crosslinker is required prior hydro-
gel usage, which may cause additional complications. For NFC, a
triggering mechanism is not required, as it is a readily injectable
hydrogel in its natural state due to its pseudoplastic and thixotro-
pic properties. This can prove to be advantageous in the use of bio-
materials as injectable hydrogels or implants, as there is no
additional toxicity or interactions introduced by external activa-
tors. Interactions between therapeutic compounds and NFC would
still require further investigation; however with the absence of
additional activation, processing or crosslinking agent removal,
the process is simpliﬁed. Additionally, the results indicate that
NFC hydrogels could show potential in the delivery of biopharma-
ceuticals, where parenteral administration could address the deliv-
ery problems of protein and peptide drugs. However it is likely that
the native NFC requires further modiﬁcations for more effective
delivery.5. Conclusions
In this study, we have demonstrated a reliable and efﬁcient
method of 99mTc-NFC labeling. Further research conducted on
NFC hydrogels with molecular imaging can be readily performed
with this methodology. In addition, our proposed method can
help in evaluating the rate of drug release with the use of phar-
macokinetic models in conjunction with molecular imaging in
drug-biomaterial studies. In the ﬁeld of non-invasive or minimal
invasive research, NFC has potential use as surgical adhesive,
space-ﬁlling biomaterial in addition to tissue engineering and
repair. We performed our study in mind of a potential controlled
release or local drug delivery hydrogel that could be easily pre-
pared and readily injected. NFC did not disintegrate or migrate
during the study despite the activity of the study animals while
awake between image acquisitions. Potential local delivery or
long-term controlled release treating chronic diseases, especially
in easily accessible areas such as the skin, could be possible with
injectable hydrogels. Removal of NFC after treatment can be per-
formed by small surgery or potentially disintegrated into glucose
by locally administering cellulose metabolizing enzymes. NFC
does not require external activators or crosslinking agents; in
addition to it being biocompatible and non-toxic. Further studies
to improve hydrogel handling or with speciﬁc therapeutic com-
pounds should be performed. However, we have shown the
potentiality of wood pulp NFC in the biomedical ﬁeld, which is
complementary to the research already done with bacterial
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